Introduction
Depression is a common co-morbid disorder in both type 1 and type 2 diabetes mellitus, and is associated with impaired quality of life (Schram et al., 2009) , poor glycemic control (Lustman et al., 2000) , increased health care costs Journal of Affective Disorders 126 (2010) 
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Journal of Affective Disorders j o u r n a l h o m e p a g e : w w w. e l s ev i e r. c o m / l o c a t e / j a d (Egede et al., 2002) , and an increased all-cause mortality rate (Egede et al., 2005) . Cognitive behavioral therapy, tricyclic antidepressants (TCAs), and selective serotonin reuptake inhibitors (SSRIs) are effective treatments for major depression in diabetic patients (Lustman and Clouse, 2002) . However, a considerable percentage of diabetic subjects receiving antidepressant drugs does not achieve full remission (TCAs: 43% and SSRIs: 52%) (Lustman and Clouse, 2002) . This finding highlights the need for further research on ways how to improve treatment efficacy in depressed patients with diabetes. One candidate that could improve treatment success may be longer chain ω-3 polyunsaturated fatty acids (PUFAs) from fatty fish, including eicosapentaenoic acid (EPA; C20:5 ω-3) and docosahexaenoic acid (DHA; C22:6 ω-3) (Pouwer et al., 2005) . Both depressed patients and diabetic patients are known to have relatively low levels of ω-3 PUFAs (Decsi et al., 2007; Sontrop and Campbell, 2006; Vessby, 2000) . A recent meta-analysis showed that ω-3 PUFAs were efficacious as antidepressant therapy (Appleton et al., 2010) , although heterogeneity in study design was noted. However, a recent study did not observe an effect of ω-3 PUFAs on mood in depressed patients with a coronary heart disease (Carney et al., 2009 ). Furthermore, there is some evidence that EPA may be particularly effective as add-on treatment in patients with major depression using antidepressant medication (Pouwer et al., 2005; Sarris et al., 2009 ). The exact mechanisms of the relationship between depression and ω-3 PUFAs remain to be elucidated, but could include increased membrane fluidity, altered cellular signaling processes, altered neurotransmitter processing, and increased antiinflammatory activity (Parker et al., 2006; Pouwer et al., 2005; Sarris et al., 2009 ). The efficacy of ω-3 PUFAs on depressive symptoms in patients with diabetes mellitus is unknown. Therefore, we conducted a double-blind, randomized, placebo-controlled study to test the efficacy of add-on ω-3 ethyl-eicosapentaenoic acid (E-EPA) on depressive symptoms in depressed diabetic patients using antidepressant medication.
Methods

Study design and participants
Participants were recruited from the VUMC diabetes outpatient clinic and through advertisements on websites, in newspapers, and patient magazines. Patients were eligible if they were aged 18-75 years, diagnosed with diabetes (type 1 or type 2), and currently being on antidepressant medication for at least two months. Furthermore, participants had to meet the criteria for current Major Depressive Disorder (MDD), determined with the Composite International Diagnostic Interview (Andrews and Peters, 1998) . Diabetes was verified with the medical status when the patient attended the VUMC. For those who were not patients of the VUMC, persons who used insulin or oral hypoglycemic agents were regarded as diabetes patients.
Exclusion criteria were: serious co-morbid disease, using fish oil supplementation, consuming more than three servings of fish per week, alcohol or drugs abuse, suicidal ideation, and/or allergy to fish, fish products or rapeseed oil.
Participants were recruited from April 2006 until May 2007 and the trial was performed between June 2006 and July 2007. The study protocol was approved by the ethical committee of the VU University Medical Center (VUMC). All participants gave informed consent.
Intervention
Patients were randomly allocated to 1 g/day E-EPA or to an equivalent dose of rapeseed oil + medium chain triglycerides (placebo) for 12 weeks. This dosage and duration are in line with other trials of ω-3 on depression (Appleton et al., 2010; Peet and Horrobin, 2002) . Both intervention and placebo medication were provided in two soft gelatin capsules per day, stabilized with mixed tocopherols, and were produced by Minami Nutrition, Belgium. Patients were advised not to chew the capsules. Patients, research nurse and researchers were blinded toward treatment allocation until completion of the data collection.
Measurements
At baseline, demographic, anthropomorphic and healthrelated characteristics were assessed at the VUMC. Severity of depressive symptoms was assessed by the Dutch version of the 10-item Montgomery Åsberg Depression Rating Scale (MADRS) (Hartong and Goekoop, 1985) , with a score range of 0-60. Higher scores reflect more severe depression.
The MADRS was administered at seven times during the study by the research nurse. At baseline and in week 12, the MADRS was administered in the VUMC. In week 1, 3, 5, 7, and 9 measurements of the MADRS were obtained per telephone. A validation study showed that the MADRS can be reliably administered by telephone instead of face-to-face (Hermens et al., 2006) . Furthermore, in weeks 1, 3, 5, 7, 9, and 12 the research nurse assessed whether the patient experienced one of the following side effects: abdominal pain, belching, diarrhea, and nausea. Other side effects were also noted. To study concealment, patients were asked whether they thought to be allocated in the E-EPA group or the placebo group in week 12.
Blood samples
Blood was collected by venipuncture at baseline and in week 12 and analyzed by the National Institute for Public Health and the Environment. EPA levels in erythrocyte phospholipids were measured with a gas chromatograph (GC-3900, Varian Assoc., Palo Alto, USA). The EPA content was expressed as percentage of the total fatty acids present in the chromatogram. Hemoglobin A 1c (HbA 1c ) is an indicator for glycemic control (normal values: 4.3-6.1%) (Jeffcoate, 2004) and was measured by a turbidimetric immuno inhibition method using an auto analyzer (LX20-Pro, Beckman-Coulter, Fullerton, USA).
Statistical analyses
Sample size was calculated with G*Power 3.0.10 for the within-between interaction in Analysis of Variance (ANOVA). Because we obtained seven repeated measures of depression symptom severity using the MADRS, 10 patients had to be included in each treatment arm to detect an effect size of 0.25 (power = 80%, two-sided α = 0.05, correlation between repeated measures = 0.6 and non-sphericity correction ε = 0.6). Assuming a drop-out rate of 20% we had to include a total of 25 patients.
Intention to treat analyses were conducted. Because MANOVA for repeated measures has low power in small samples (Stevens, 2002) , the course of depression symptoms was compared between both groups using ANOVA for repeated measures by testing the significance of the interaction term treatment ⁎ time, adjusted for the Greenhouse-Geisser epsilon. Sensitivity analyses were performed by excluding one person who discontinued E-EPA treatment and two participants in the placebo arm who discontinued using antidepressants during the study. The standardized effect size was calculated by dividing the difference of change in MADRS scores (from baseline to 12-week follow-up) between the E-EPA and placebo group by their pooled standard deviations. In all analyses, a 2-sided p value of b0.05 was used to determine statistical significance. Statistical analyses were performed with SPSS version 16.0 for Windows. willing to participate in the study. Thirty-five patients declined after they had received more detailed information about the study. Furthermore, twelve patients were excluded because they did not meet the inclusion criteria. The 25 eligible persons for the trial were randomly assigned to either the E-EPA group (N = 13) and the placebo group (N = 12). One patient receiving E-EPA was lost to follow-up. From all other randomized patients, all follow-up measurements were available. One participant discontinued treatment during the trial due to an allergic reaction to E-EPA (see below). Two participants (both from the placebo group) ceased using antidepressants during the trial. Table 1 provides the baseline characteristics of the participants assigned to E-EPA and placebo.
Results
Participant flow
EPA levels in erythrocyte membrane
From baseline to 12-week follow-up, the mean level of EPA in the erythrocyte membrane tripled in the E-EPA group (from 0.53% (± 0.17) to (1.69%; ± 0.56)), whereas it remained stable in the placebo group (from 0.66% (±0.20) to (0.61%; ± 0.19)) supporting the integrity of the intervention arms.
Course of depression symptom severity measured with the MADRS
At baseline, the mean MADRS score was 26.3 (± 8.2) in the E-EPA group and 26.4 (± 8.7) in the placebo group. At 12-week follow-up, the mean MADRS scores dropped to 14.0 (± 6.9) in the E-EPA group and to 11.6 (± 9.1) in the placebo group (standardized effect size favoring placebo d = 0.29). Fig. 2 shows the development of the MADRS score for the E-EPA group and the placebo group over time. Repeated measures analysis revealed a statistically significant time effect: mean MADRS score decreased over time in both groups (F = 21.14, df = 3.98, p b 0.001). However, no significant effect of E-EPA treatment versus placebo over time was found (treatment ⁎ time interaction ANOVA F = 1.63, df = 3.98, p = 0.17). Excluding one participant who ceased using E-EPA during the study and two patients who discontinued using antidepressants marginally changed the results of the ANOVA (treatment ⁎ time interaction F = 1.21, df = 3.93, p = 0.31). Furthermore, in the E-EPA group, change in depression severity and change in E-EPA level from baseline to 12-week follow-up were uncorrelated (Pearson's r = 0.016, p = 0.96).
Side effects
Side effects were assessed at six occasions. Eight persons never had a side effect. Prevalent side effects were stomach ache (N = 10), belching (N = 7), nausea (N = 6), and diarrhea (N = 5). Number and type of side effects did not differ significantly between the E-EPA and the placebo group. One person assigned to the E-EPA group showed an allergic reaction during the trial which consisted of rashes and itching. No other serious side effects were reported.
Concealment
Concealment appeared to be successful. At 12-week follow-up, only 4 of the 12 participants (33%) correctly thought they received E-EPA, and 4 of the 12 (33%) participants correctly thought they received the placebo.
Discussion
In the present randomized, double-blind placebo-controlled study, we found no evidence of a therapeutic effect of 1 g/day E-EPA as an add-on to antidepressant medication compared to placebo in patients with diabetes and MDD during 12 weeks. This finding is not likely to be explained by a lack of contrast between the two groups, as we observed tripled levels of EPA in the erythrocyte membranes of participants in the intervention group and no change in the placebo group.
In a recent meta-analysis, Appleton et al. (2010) concluded that ω-3 PUFAs showed antidepressant efficacy in nondiabetic depressed patients, yet significant heterogeneity in study design was noted. Our results are in line with a recent randomized controlled trial in coronary heart disease patients with major depression that did not find evidence that ω-3 (Muller et al., 2000) . d At 12-week follow-up. Treatment was not specified for 1 person in the E-EPA arm (loss to follow-up) and for 1 person in the placebo arm. PUFAs augmentation of sertraline was superior to sertraline plus placebo for the treatment of depression (Carney et al., 2009) . However, there are clear differences between our study and the other studies in sample characteristics (diabetes patients vs. other patient groups) and the ω-3 PUFAs provided. Although EPA showed more promising results on depression than DHA monotherapy (Pouwer et al., 2005) , it might be that a specific ratio of DHA and EPA is more effective. Strengths of our study included the small number of loss to follow-up, the large number of follow-up measurements, and its double-blind, placebo-controlled design. However, the study is also subject to some limitations. Information about fish consumption was only assessed at baseline. Yet, there was no indication that the placebo group increased fish consumption as the level of EPA did not increase. Also, we had a heterogeneous sample of patients with respect to type of diabetes and antidepressant use. In the case that E-EPA would be more effective in either type of diabetes or as add-on to a specific type of antidepressant, our study sample was too small to detect these effects. Furthermore, the dose of fish oil in our study (1 g/day) and duration might not have been adequate for patients with diabetes. Although we could not find studies about the effect of the placebo (rapeseed oil) on mood, we cannot fully exclude the possibility that rapeseed oil has some beneficial effect on mood. Finally, although we assessed the power of our study rigorously, we are aware that our sample size is smaller than most other randomized controlled trials. Therefore, the results may be more sensitive for chance fluctuations and warrant future replication studies.
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